Impact of Appropriate Antimicrobial Therapy for Patients with Severe Sepsis and Septic Shock – A Quality Improvement Study

Paula K. O. Yokota¹, Alexandre R. Marra¹*, Marines D. V. Martino², Elivane S. Victor³, Marcelino S. Durão¹, Michael B. Edmond⁴, Oscar F. P. dos Santos¹

¹ Division of Medical Practice, Hospital Israelita Albert Einstein, São Paulo, Brazil, ²Laboratory of Microbiology, Hospital Israelita Albert Einstein, São Paulo, Brazil, ³Statistics Department, Instituto Israelita de Ensino e Pesquisa (IIEP), Hospital Israelita Albert Einstein, São Paulo, Brazil, ⁴Department of Internal Medicine, Virginia Commonwealth University School of Medicine, Richmond, Virginia, United States of America

Abstract

Background: There is ample literature available on the association between both time to antibiotics and appropriateness of antibiotics and clinical outcomes from sepsis. In fact, the current state of debate surrounds the balance to be struck between prompt empirical therapy and care in the choice of appropriate antibiotics (both in terms of the susceptibility of infecting organism and minimizing resistance arising from use of broad-spectrum agents). The objective of this study is to determine sepsis bundle compliance and the appropriateness of antimicrobial therapy in patients with severe sepsis and septic shock and its impact on outcomes.

Material: This study was conducted in the ICU of a tertiary care, private hospital in São Paulo, Brazil. A retrospective cohort study was conducted from July 2005 to December 2012 in patients with severe sepsis and septic shock.

Results: A total of 1,279 patients were identified with severe sepsis and septic shock, of which 358 (32.1%) had bloodstream infection (BSI). The inpatient mortality rate was 29%. In evaluation of the sepsis bundle, over time there was a progressive increase in serum arterial lactate collection, obtaining blood cultures prior to antibiotic administration, administration of broad-spectrum antibiotics within 1 hour, and administration of appropriate antimicrobials, with statistically significant differences in the later years of the study. We also observed a significant decrease in mortality. In patients with bloodstream infection, after adjustment for other covariates the administration of appropriate antimicrobial therapy was associated with a decrease in mortality in patients with severe sepsis and septic shock (p = 0.023).

Conclusions: The administration of appropriate antimicrobial therapy was independently associated with a decline in mortality in patients with severe sepsis and septic shock due to bloodstream infection. As protocol adherence increased over time, the crude mortality rate decreased, which reinforces the need to implement institutional guidelines and monitor appropriate antimicrobial therapy compliance.

Background

Severe sepsis and septic shock are worrisome manifestations of systemic infection and the leading causes of hospitalization in intensive care units (ICUs), where an estimated 19 million cases occur worldwide each year, resulting in the death of one in four of these patients [1,2]. According to the Ministry of Health of Brazil, severe sepsis and septic shock are responsible for an average of 41% of the total yearly in-hospital mortality for adults from 2008 through August 2013. Case mortality is 46% in the southeast region [3], which reinforced our desire to participate in the Surviving Sepsis Campaign beginning in 2004, as well as the “Stop Sepsis, Save Lives” project [4,5].

According to the international guidelines, for the immediate treatment of severe sepsis or septic shock, antibiotic administration should occur within the first hour of recognition as it directly impacts in mortality [2]. Since 2006, we have utilized the sepsis bundle in our ICU [6], the treatment recommendations were organized in two bundles: a resuscitation bundle (6 tasks to begin immediately and to be accomplished within 6 hours) and a management bundle (4 tasks to be completed within 24 hours) [4]; however, there is no evaluation of the appropriateness of antimicrobial therapy after collecting blood cultures in sepsis bundle studies, which is one of the main measures to reduce mortality in critically ill patients suffering from infectious processes. When longer time frames to appropriate antibiotic therapy are observed there is an increased risk of death [7–9].
Thus, the objectives of the study were to determine i) the sepsis bundle compliance, ii) as well as the appropriateness of antimicrobial therapy for patients with severe sepsis and septic shock, as well as impact on outcomes.

Methods

This study was conducted in the ICU of a tertiary care, private hospital in São Paulo, Brazil. This open model ICU is a 41-bed medical-surgical unit with approximately 10,500 patient-days yearly. A retrospective cohort study was conducted from July 2005 to December 2012 in patients with severe sepsis and septic shock to analyze the impact of appropriate antimicrobial therapy. This study was a quality improvement project that was approved by the Institutional Review Board (IRB) of Hospital Israelita Albert Einstein. The requirements for informed consent were waived by our IRB in accordance of the Code of Federal Regulation and of the Privacy Rule. This project includes data from our previous sepsis bundle study from July 2005 to December 2009 [6] with the addition of observations for the period from January 2010 to December 2012 in order to evaluate whether sustained implementation of the sepsis bundle in our ICU could effectively reduce mortality in severe sepsis and septic shock patients.

Sepsis was defined as infection plus two or more of the following SIRS criteria: T>38°C or <36°C; heart rate >90/min; respiratory rate >20 breaths/min (or Paco2<32 mm Hg); or WBC count, >12,000 cells/μL or <4,000 cells/μL (or >10% band forms) [10]. Severe sepsis was defined as sepsis plus organ dysfunction, hypotension, or hypoperfusion abnormalities, including lactic acidosis, oliguria, or encephalopathy. Septic shock was defined as sepsis-induced hypotension (ie, systolic BP, <90 mm Hg or a drop of >40 mm Hg in the absence of other cause of hypotension) plus hypoperfusion abnormalities despite adequate fluid resuscitation [10] (Appendix S1). Infection was defined according to the definitions of the International Sepsis Forum [11] and adjudicated by the patient’s physician.

The data collected included age, gender, admission date, the time when severe sepsis or septic shock was diagnosed, location before ICU admission, hospital and ICU length of stay, organ dysfunction at the time of diagnosis, APACHE II score on admission, and outcome status (death was defined as in-hospital mortality). As per the Surviving Sepsis Campaign, “time zero” was defined as the time of diagnosis of severe sepsis or septic shock.

Once a patient meets the bundle initiation criteria, the 6-hour bundle was initiated by collecting serum arterial lactate and obtaining blood cultures before antibiotic administration (Appendix S1). From the time of severe sepsis (time zero), broad-spectrum antibiotics are to be administered within 1 hour (since every hour of delay increases the risk of poorer outcomes). Hypotension and/or elevated lactate are treated with IV fluids; in the event of persistent hypotension despite fluid resuscitation (septic shock) and/or lactate >4 mmol/L (>36 mg/dL), maintaining adequate central venous pressure and central venous oxygen saturation are indicated. Patients who do not have septic shock and elevated lactate >4 mmol/L (>36 mg/dL) do not require measurement of central venous pressure and central venous oxygen saturation.

The first 24-hour management bundle includes optimization of glycemic control, respiratory inspiratory plateau pressure, and determination of the need for corticosteroids and drotrecogin alfa (activated) [4]. However, we did not perform analysis for the 24-hour sepsis bundle for patients with severe sepsis or septic shock because there have been changes in the recommendations (e.g., glycemic control, and use of activated protein C) [2,6].

Our hospital has an electronic system for activating a team dedicated to diagnosing and treating severe sepsis and septic shock patients immediately. The ICU doctor and the nurse manager are simultaneously notified. The development of this sepsis team was part of implementing the sepsis bundle. Our hospital also has had a rapid response team since 2007 [6]. The rapid response team is alerted based on the following criteria: respiratory problems such as acute decrease in oxygen saturation <90% and change in respiratory rate to <8/minute or >28/minute; circulatory problems: decrease in systolic arterial pressure to <90 mmHg associated with symptoms; and change in heart rate to <40 bpm or >130 bpm; neurologic problems: decreasing consciousness levels or seizures; or a serious concern with the patient’s overall condition (patient claims to be feeling unwell or has the sensation “something is not right”), and change in color, diaphoresis, or coolness of the extremities. Some of these described signs are the same as those noted in sepsis patients [6,12].

Antimicrobial therapy

Antimicrobial therapy was considered appropriate if the bacteria identified in blood culture was susceptible to at least one of the antibiotics administered within 24 hours after the collection of culture. If the isolated microorganism was not susceptible by in vitro testing to the antibiotic used, the therapy was considered inadequate [7]. The microbiology laboratory has an alert system to notify physicians of patients with positive blood cultures and their gram stain results.

Microbiological methods

All samples were identified by manual or automated method and confirmed using the Vitek 2 (bio-Mérieux Vitek, Inc., Hazelwood, MO) system. To determine the prevalence of antimicrobial resistance, the same organism with identical antimicrobial profiles from the same or different anatomic sites in the same patient were considered a single isolate. Antimicrobial susceptibility testing was performed by an automated method or by disk diffusion as described by the Clinical and Laboratory Standards Institute (CLSI) [13].

Statistical analysis

Differences over time were evaluated by autoregressive time series models. The order of the models was determined according to the analysis of the partial autocorrelation function of residuals. The summary of the year was presented as means ± standard deviations or as absolute frequencies and percentages. Significance of changes was evaluated by trend effects. All tests of significance are two-tailed and alpha was set at 0.05.

To analyze the impact of inadequate antimicrobial therapy on mortality in the 358 patients with bloodstream infection, models were constructed by binary logistic regression in single and multiple approaches, only with data collected between 2010 and 2012. The variables with p≤0.10 in the simple analysis models were evaluated via multivariate analysis. The association of independent variables was expressed as odds ratios with 95% confidence intervals.

Analyses were performed with the Statistical Package for the Social Sciences 17.0 (Chicago, IL, USA).

Results

The total cohort, shown in Figure S1, consisted of 1,279 consecutive patients, where 57.7% (N = 738) were male, mean age ± standard deviation (SD) 67±18 years, mean APACHE II score...
Table 1. Demographic and clinical characteristics of severe sepsis and septic shock patients from July 2005 to December 2012.

| Variables                        | Before protocol | After protocol |
|----------------------------------|-----------------|----------------|
|                                  | 07/05 a 04/06   | 05/06 a 12/06  | 07/07 | 08/08 | 09/09 | 10/10 | 11/11 | 12/12 |
|                                  | (n = 100)       | (n = 73)       | (n = 140) | (n = 134) | (n = 117) | (n = 197) | (n = 240) | (n = 279) |
| Septic shock                     | 88 88.0%        | 62 84.9%       | 108 77.1% | 100 75.2% | 68 58.1% | 116 58.9% | 152 63.3% | 182 65.2% |
| APACHE                           | 25 ± 8          | 25 ± 9         | 24 ± 7 | 23 ± 6 | 21 ± 6 | 19 ± 7 | 21 ± 7 | 23 ± 7 |
| Age                              | 63 ± 20         | 66 ± 20        | 67 ± 19 | 67 ± 17 | 67 ± 18 | 69 ± 18 | 67 ± 18 | 66 ± 18 |
| Serum arterial lactate           | 72 72.0%        | 68 93.2%       | 121 86.4% | 123 92.5% | 96 82.1% | 183 92.9% | 231 96.3% | 274 98.2% |
| Blood culture prior to antibiotic administration | 44 44.0% | 42 57.5% | 67 47.9 | 99 74.4 | 85 72.6 | 171 86.8 | 232 96.7 | 270 96.8 |
| Positive blood culture           | 23 43.4%        | 27 34.6%       | 37 39.4% | 41 37.3% | 31 28.7% | 52 30.4% | 75 32.3% | 72 26.7% |
| Broad-spectrum antibiotic within 1 h | 58 58.0% | 46 63.0 | 105 75.0 | 103 77.4 | 73 62.4 | 105 53.3 | 137 57.1 | 228 81.7 |
| Central venous oxygen saturation (ScvO$_2$≥ 70%) | 50 50.0% | 34 46.6 | 60 42.9 | 64 48.1 | 66 56.4 | 59 95.2 | 100 76.9 | 103 64.8 |
| Appropriate antibiotic therapy   | 13 56.5%        | 19 70.4%       | 19 51.4% | 32 78.0% | 26 83.9% | 40 76.9 | 52 69.3 | 59 81.9 |
| Mortality Rate                   | 54 54.0%        | 30 41.1%       | 55 39.3% | 55 41.4% | 19 16.2% | 61 31.0 | 46 19.2 | 49 17.6 |

- Analyses of antimicrobial appropriateness and value of central venous oxygen saturation were performed with the total of 199 and 358 patients, respectively.
- Extended data from the study published in Plos One 2011 (reference number 6).

doi:10.1371/journal.pone.0104475.t001
administration of antibiotic was 2.5 (6) (Table 5).

Escherichia coli (93.0%) had monobacterial infections (table 6). The most common antimicrobial therapy (p = 0.023) (Table 4). Higher APACHE II scores and the presence of polymicrobial infection were associated with inadequate therapy; however, we were not able to demonstrate this by the multivariate analysis (table 5).

**Discussion**

With improvement of compliance to the sepsis bundle over time, we demonstrate an association with reduced mortality. Not surprisingly, risk factors for death include the APACHE II score, as well as the presence of other disorders that contribute to severe worsening of the patient’s general condition [1].

In addition to implementing the sepsis protocol at our institution (May 2006), practical bedside contact with evidence-based medicine and attendance at several scientific meetings by the multidisciplinary team also contributed in improving the care of these patients. Over the period of analysis, changes in treatment, such as the utilization of Activated protein C followed by its suspension reflect the need for continuous learning and improving based on the state of the science [6].

Another important fact, demonstrated by logistic regression, is that despite the implementation of the measures incorporated in the sepsis bundle, such as collecting serum arterial lactate and timely administration of antibiotics, it was antimicrobial appropriateness that contributed to decreased mortality in severe sepsis and septic shock patients. Over the past two years, our mortality rate in severe sepsis and septic shock patients was below 20% as
Table 3. Risk factors associated with death in all patients with severe sepsis or septic shock.

| Variables                        | Survival (N = 908) | Death (N = 371) | Univariate analysis | Multivariate analysis |
|----------------------------------|--------------------|-----------------|---------------------|-----------------------|
|                                  | N (%)              | N (%)           | OR                  | CI 95%                | P          | OR                  | CI 95% | P          |
|                                  |                    |                 | Min                 | Max                   |            | Min                 | Max     |            |
| Age (years), mean ± SD          | 65.9± 18           | 69.2± 18        | 1.010               | 1.003                 | 1.017     | 0.004               | 1.004   | 0.997     | 1.012     | 0.263 |
| APACHE II, mean ± SD            | 16.2± 9            | 21.8± 10        | 1.060               | 1.046                 | 1.074     | <0.001              | 1.052   | 1.037     | 1.067     | <0.001 |
| Liver dysfunction               | 48 (5.2)           | 20 (5.3)        | 1.021               | 0.597                 | 1.745     | 0.940               |         |           |           |       |
| Cardiac dysfunction             | 595 (97.8)         | 287 (77.3)      | 1.797               | 1.360                 | 2.376     | <0.001              | 1.439   | 1.048     | 1.976     | 0.025 |
| Renal dysfunction               | 307 (33.8)         | 204 (54.9)      | 2.391               | 1.869                 | 3.060     | <0.001              | 1.792   | 1.371     | 2.341     | <0.001 |
| Hematologic dysfunction         | 307 (33.8)         | 155 (41.7)      | 1.405               | 1.096                 | 1.800     | 0.007               | 1.684   | 1.270     | 2.234     | <0.001 |
| Respiratory dysfunction         | 576 (63.4)         | 255 (68.7)      | 1.267               | 0.979                 | 1.640     | 0.072               | 1.693   | 1.265     | 2.266     | <0.001 |
| Neurologic dysfunction          | 283 (31.2)         | 142 (38.2)      | 1.369               | 1.064                 | 1.762     | 0.015               | 1.286   | 0.976     | 1.694     | 0.073 |
| Blood cultures prior to antibiotic administration | 830 (91.4)         | 286 (77.0)      | 0.316               | 0.226                 | 0.442     | <0.001              | 0.380   | 0.264     | 0.546     | <0.001 |
| Broad-spectrum antibiotic within 1 hour | 585 (64.4)         | 206 (55.5)      | 0.689               | 0.539                 | 0.881     | <0.001              | 0.771   | 0.589     | 1.010     | 0.060 |
| Serum arterial lactate          | 884 (97.4)         | 350 (94.3)      | 0.452               | 0.249                 | 0.823     | 0.009               | 1.383   | 1.037     | 1.845     | 0.027 |
| Central venous oxygen saturation | 493 (54.3)         | 255 (68.7)      | 1.850               | 1.433                 | 2.389     | <0.001              | 0.392   | 0.203     | 0.757     | 0.005 |

OR = Odds Ratio; CI = Confidence Interval; APACHE: Acute Physiology and Chronic Health Evaluation II.

doi:10.1371/journal.pone.0104475.t003
| Variables                        | Survival (N = 257) | Death (N = 101) | Univariate analysis | Multivariate analysis |
|---------------------------------|--------------------|----------------|---------------------|-----------------------|
|                                 | N (%)              | N (%)          | OR                  | CI 95%                | Min  | Max  | P    | OR  | CI 95% | Min  | Max  | P     |
| Age (years), mean ± SD          | 64.5 ± 17          | 63.2 ± 19      | 0.996               | 0.983 - 1.009         | 0.521 |
| APACHE II, mean ± SD            | 16.9 ± 10          | 21.0 ± 11      | 1.041               | 1.017 - 1.066         | 0.001 | 1.029 | 1.004 | 1.055 | 0.022  |
| Liver dysfunction               | 19 (7.4)           | 08 (7.9)       | 1.078               | 0.456 - 2.547         | 0.865 |
| Cardiac dysfunction             | 189 (73.5)         | 84 (83.2)      | 1.778               | 0.985 - 3.208         | 0.056 | 1.392 | 0.746 | 2.595 | 0.299  |
| Renal dysfunction               | 81 (31.5)          | 57 (56.4)      | 2.815               | 1.754 - 4.518         | <0.001 | 2.432 | 1.472 | 4.018 | 0.001  |
| Hematologic dysfunction         | 89 (34.6)          | 45 (44.6)      | 1.517               | 0.949 - 2.425         | 0.082 | 1.383 | 0.953 | 2.628 | 0.076  |
| Respiratory dysfunction         | 144 (56.0)         | 66 (65.3)      | 1.480               | 0.917 - 2.387         | 0.108 |
| Neurologic dysfunction          | 74 (28.8)          | 45 (44.6)      | 1.987               | 1.234 - 3.200         | 0.005 | 1.908 | 1.153 | 3.158 | 0.012  |
| Broad-spectrum antibiotic within 1 hour | 160 (62.3)  | 60 (59.4)      | 0.887               | 0.554 - 1.420         | 0.618 |
| Adequate antimicrobial therapy  | 197 (76.7)         | 63 (62.4)      | 0.505               | 0.308 - 0.829         | 0.007 | 0.536 | 0.314 | 0.916 | 0.023  |
| Serum arterial lactate          | 252 (98.1)         | 97 (96.0)      | 0.481               | 0.127 - 1.829         | 0.283 |
| Central venous oxygen saturation| 161 (62.6)         | 71 (70.3)      | 1.411               | 0.859 - 2.317         | 0.174 |

OR = Odds Ratio; CI = Confidence Interval; APACHE = Acute Physiology and Chronic Health Evaluation II.

doi:10.1371/journal.pone.0104475.t004
Table 5. Risk factors associated with inadequate antimicrobial therapy in patients with severe sepsis or septic shock patients who had documented bloodstream infection.

| Variables                                | Adequate antimicrobial therapy | Univariate analysis | Multivariate analysis |
|------------------------------------------|--------------------------------|---------------------|-----------------------|
|                                          | No (N = 98)                   | Yes (N = 260)       |                       |
|                                          | N (%)                         | N (%)               | OR  CI 95% p          | OR  CI 95% p          |
| Male                                     | 63 (28.5)                     | 158 (71.5)          | 1.162 0.717 1.882 0.542 |
| Age (years), mean ± SD                   | 65±20                         | 64±17               | 1.005 0.991 1.018 0.495 |
| APACHE II, mean ± SD                     | 21±11                         | 17±10               | 1.044 1.02 1.069 <0.001 | 1.048 1.023 1.074 <0.001 |
| Liver dysfunction                         | 05 (18.5)                     | 22 (81.5)           | 0.582 0.214 1.581 0.288 |
| Cardiac dysfunction                       | 78 (28.6)                     | 195 (71.4)          | 1.3 0.738 2.289 0.363 |
| Renal dysfunction                         | 37 (26.8)                     | 101 (73.2)          | 0.955 0.592 1.541 0.85 |
| Hematologic dysfunction                   | 39 (29.1)                     | 95 (70.9)           | 1.148 0.713 1.849 0.57 |
| Respiratory dysfunction                   | 55 (26.2)                     | 155 (73.8)          | 0.866 0.542 1.386 0.55 |
| Neurologic dysfunction                    | 32 (26.9)                     | 87 (73.1)           | 0.964 0.588 1.581 0.885 |
| Polymicrobial infection                   | 12 (48.0)                     | 13 (52.0)           | 2.651 1.165 6.032 0.02 | 2.954 1.227 7.115 0.016 |
| ESKAPE pathogen causing bloodstream infection | 44 (33.3)                     | 88 (66.7)           | 1.593 0.992 2.558 0.054 | 1.436 0.872 2.366 0.155 |

OR = Odds Ratio; CI = Confidence Interval; APACHE = Acute Physiology and Chronic Health Evaluation II.
ESKAPE = Enterococcus, Staphylococcus aureus, Klebsiella pneumoniae, Pseudomonas aeruginosa, Enterobacter spp.
doi:10.1371/journal.pone.0104475.t005
**Table 6.** The most prevalent microorganisms from monomicrobial bloodstream infections and clinical outcome stratified by adequacy of antimicrobial therapy during the study period.

| Microorganisms          | All organisms | Death | Survival | Resistant organisms | Death | Survival |
|-------------------------|---------------|-------|----------|---------------------|-------|----------|
|                         | N (%)         | Adequate ATB | Inadequate ATB | N (%) | Adequate ATB | Inadequate ATB | N (%) | Adequate ATB | Inadequate ATB | N (%) | Adequate ATB | Inadequate ATB |
| Fungi (N = 5, 1.5%)     |               |       |          |                    |       |          |                    |       |          |                    |       |
| *Candida albicans*      | 02            | -     | 01       | -                  | no    | -        | -                  | -     | -        | -                  |
|                         | (40.0)        | (50.0) | (50.0) |                    |       |          |                    |       |          |                    |
| *Candida krusei*        | 01            | -     | -        | -                  | 01*   | -        | -                  | -     | -        | 01                  |
|                         | (20.0)        |       |          |                    | (100.0) | (100.0) |                    |       |          | (100.0)              |
| *Candida parapsilosis*  | 02            | -     | 02       | -                  | no    | -        | -                  | -     | -        | -                  |
|                         | (40.0)        | (100.0) |       |                    |       |          |                    |       |          |                    |
| Gram negative (N = 190; 57.1%) |         |       |          |                    |       |          |                    |       |          |                    |
| *Escherichia coli*      | 101           | 13    | 05       | 77                 | 06    | 07**    | 01                 | 04    | 02       | -                  |
|                         | (53.1)        | (12.8) | (4.9)    | (36.2)             | (6.1) | (6.9)    | (14.2)             | (57.3) | (28.5)    |                    |
| *Pseudomonas aeruginosa*| 18            | 07    | 04       | 06                 | 01    | 08**    | 02                 | 04    | 02       | -                  |
|                         | (10.0)        | (38.9) | (22.2)   | (33.3)             | (5.6) | (44.4)   | (25.0)             | (50.0) | (25.0)    |                    |
| *Acinetobacter spp*     | 8             | 02    | 01       | 04                 | 01    | 01**    | -                  | 01    | -        | -                  |
|                         | (4.2)         | (25.0) | (12.5)   | (50.0)             | (12.5) | (12.5)   | (100.0)            |       |          |                    |
| *Klebsiella spp*        | 24            | 03    | 04       | 13                 | 04    | 10**    | 01                 | 03    | 03       | 03                  |
|                         | (12.6)        | (12.5) | (16.6)   | (54.3)             | (16.6) | (41.2)   | (10.0)             | (30.0) | (30.0)    | (30.0)              |
| Gram positive (N = 138; 41.4%) |         |       |          |                    |       |          |                    |       |          |                    |
| *Staphylococcus aureus* | 24            | 07    | 04       | 02                 | 11    | 11**    | 06                 | 04    | 01       | -                  |
|                         | (17.3)        | (29.2) | (16.6)   | (8.4)              | (45.8) | (45.8)   | (54.5)             | (36.3) | (9.2)     |                    |
| *Enterococcus spp*      | 11            | 04    | 00       | 04                 | 03    | 01***   | -                  | -     | 01       | -                  |
|                         | (7.9)         | (36.3) | (0.0)    | (36.3)             | (27.4) | (9.2)    | (100.0)            |       |          |                    |
| Coagulase-negative staphylococci | 44        | 13    | 08       | 16                 | 07    | 35**    | 11                 | 08    | 11       | 05                  |
|                         | (26.1)        | (29.5) | (18.2)   | (36.4)             | (15.9) | (79.5)   | (31.4)             | (22.9) | (31.4)    | (14.3)              |

*resistant to fluconazole.
**resistant to 3rd and 4th generation cephalosporins.
*resistant to carbapenems.
##resistant to methicillin.
###resistant to vancomycin.

doi:10.1371/journal.pone.0104475.t006
Sampling for microbiological analyses, and the rapid administration of appropriate antimicrobial therapy, and outcome of patients with severe sepsis and septic shock, quick identification of the source of infection, proper etiology, antimicrobial therapy and outcome of patients with severe sepsis, and an increase in Clostridium difficile infections. In addition, some antimicrobials have side effects that require caution and rational prescribing [7–9].

While empiric antibiotic therapy is important [17], targeted therapy based on culture results should also be a goal. However, sepsis bundle evaluation studies have not examined the appropriateness of the antimicrobial therapy administered [18].

Because identification of pathogens in cultures is time intensive, one of the ways that our institution found to speed up the process of communicating blood cultures results was for laboratory staff to call the physicians responsible for the patient. Of the ESKAPE pathogens [19,20], which have paramount importance due to their pathogenesis, transmission mode and antimicrobial resistance, the most common was E. coli. However, the incidence of S. aureus (MRSA) and E. faecium (VRE) cases was low (Table 6).

Regarding the appropriateness of antibiotic selection for the cases with positive blood culture, our data show a fair rate of treatment adequacy, but in relation to fungal infections of the five cases identified 60.0% (3/5) died and none were receiving adequate therapy (Table 6). In the APACHE II study [21], calculations were done only on the day of admission. One explanation to justify why patients with higher APACHE II were associated with inadequate antimicrobial therapy was in the first 24 hours there was an underestimation of the severity of these patients and the appropriate antimicrobial therapy. If we had calculated the prognostic score on our patients at the time of severe sepsis and septic shock diagnosis, the APACHE score would likely be very different. Recently, in a similar study evaluating etiology, antimicrobial therapy and outcome of patients with severe sepsis, quick identification of the source of infection, proper sampling for microbiological analyses, and the rapid administration of appropriate antimicrobial therapy were shown to be crucial management points [22].

Study Limitations
A limitation of our study is that it was performed at a single private medical facility so it may not be generalizable to other hospitals (e.g., public facilities). In addition, data was retrospectively collected from medical records; however, because of the sepsis bundle protocol these septic patients were followed prospectively. Lastly, we did not include microbiologic data from sites other than blood cultures with regards to assessing appropriateness of antimicrobial therapy. However, cultures from nonsterile sites (e.g., respiratory tract) are more difficult to interpret since in many cases the organisms are colonizing rather than causing true infection.

Implications for policy and practice
Other improvements that were taking place may have impacted our study findings. Since 2007 our hospital has been engaged in zero tolerance for healthcare associated infections. We have observed a significant reduction in ventilator-associated pneumonia and in central venous associated bloodstream infections [23,24]. We also implemented other ICU best practices during the study period, including a glycemic control protocol [25]. We adopted intermediate glucose control, because we believe that tight glucose control is difficult to accomplish in routine intensive care unit settings and is associated with a significant increase in the incidence of hypoglycaemia [25,26]. However, it is interesting to note that the best practices for the care of patients with severe sepsis and septic shock were improving over time in our ICU. This affirms our belief that the sepsis bundle needs to be considered as the intervention decreasing mortality in septic shock and severe sepsis because of the better care and the prompt recognition of these patients in hospital [6].

Conclusions
Appropriate antimicrobial therapy and implementation of the sepsis bundle in patients with severe sepsis and septic shock due to bloodstream infection was associated with a 46% reduction in mortality. Assessment of appropriate antimicrobials should be incorporated into the Surviving Sepsis Campaign as a quality metric [18].

Supporting Information
Figure S1 Flow-diagram - Cohort selection of total patients, septic shock patients and bloodstream infection. (TIF)
Figure S2 Proportion of patients with severe sepsis and septic shock who died and sepsis bundle compliance. (TIF)
Appendix 1 Sepsis definitions. (DOCX)

Author Contributions
Conceived and designed the experiments: PKOY ARM MSD OFPS. Performed the experiments: PKOY MDVM ESV. Analyzed the data: PKOY ARM ESV. Contributed reagents/materials/analysis tools: PKOY ARM ESV. Wrote the paper: PKOY ARM MDVM ESV MSD MBE. Provided support to implement the sepsis bundle: OFPS.

References
1. Angus DC, van der Poll T (2013) Severe sepsis and septic shock. N Engl J Med 369: 840–851.
2. Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, et al. (2013) Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med 41: 580–637.
3. Ministério da Saúde. Informações de Saúde. DATASUS. Taxa de mortalidade hospitalar por local de internação – Brasil 2006 a agosto 2013. Brasília: Ministério da Saúde, DATASUS. Available: http://tabnet.datasus.gov.br/cgi/tabcgi.exe?msa/rms/aidef. Accessed: 2013 Oct 21.
4. Dellinger RP, Carlet JM, Masur H, Gerlach H, Calandra T, et al. (2004) Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Crit Care Med 32: 858–863.
5. Global Sepsis Alliance. World sepsis day. Jena: Center for Sepsis Control and Care. Available: http://www.world-sepsis-day.org. Accessed 2013 Oct 25.
6. Shiramizo SC, Marra AR, Durão Jr MS, Paes ATT, Edmond MB, et al. (2011) Decreasing mortality in severe sepsis and septic shock patients by implementing a sepsis bundle in a hospital setting. PLoS One 6 (11): e26790.
7. Ibrahim EH, Sherman G, Ward S, Fraser VJ, Kollef M (2000) The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest 118: 146–155.
8. Zaragoza R, Artero A, Camarena JJ, Sancho S, Gonzales R, et al. (2003) The influence of inadequate empirical antimicrobial treatment on patients with bloodstream infections in an intensive care unit. Clin Microbiol Infect 9: 412–418.

9. Kang CI, Kim SH, Kim HB, Park SW, Choe VJ, et al. (2003) Pseudomonas aeruginosa bacteremia: risk factors for mortality and influence of delayed receipt of effective antimicrobial therapy on clinical outcome. Clin Infect Dis 37: 745–751.

10. Bone RC, Balk RA, Dellinger RP, Fein AM, et al. (1992) Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 101: 1644–1655.

11. Calandra T, Cohen J (2005) International Sepsis Forum Definition of Infection in the ICU Consensus Conference. The International sepsis forum consensus conference on definitions of infection in the intensive care unit. Crit Care Med 33: 1538–48.

12. Gonçales PDS, Polessi JA, Bass LM, Santos GPD, Yokota PKO, et al. (2012) Reduced frequency of cardiopulmonary arrest by rapid response teams. Einstein (São Paulo) 10: 442–448.

13. Clinical and Laboratory Standards Institute (2006) Performance Standards for antimicrobial susceptibility testing: sixteenth informational supplement. CLSI document M100-S16.Wayne, PA: CLSI.

14. Proudfoot AG, McAuley DF, Hind M, Griffiths MJD (2011) Translational research: what does it mean, what has it delivered and what might it deliver? Curr Opin Crit Care 17: 495–503.

15. Cardoso T, Ribeiro O, Aragão I, Costa-Pereira A, Sarmento A (2013) The impact of healthcare-associated infection on mortality: failure in clinical recognition is related with inadequate antibiotic therapy. PloS ONE 8(5): e61418.

16. Zuebert S, Funk DJ, Kumar A (2010) Antibiotics in sepsis and septic shock: like everything else in life, timing is everything. Crit Care Med 38: 1211–1212.

17. Giaieski DF, Mikkelsen ME, Band RA, Pines JM, Massone R, et al. (2010) Impact of time to antibiotics on survival in patients with severe sepsis or septic shock in whom early goal-directed therapy was initiated in the emergency department. Crit Care Med 38: 1045–1053.

18. Barochia AV, Cui X, Eichacker PQ (2013) The surviving sepsis campaign’s revised sepsis bundles. Curr Infect Dis Rep 15: 395–395.

19. Rice LB (2008) Federal funding for the study of antimicrobial resistance in nosocomial pathogens: no ESKAPE! J Infect Dis 197: 1079–1081.

20. Boucher HW, Talbot GH, Bradley JS, Edwards JE Jr, Gilbert D, et al. (2009) Bad bugs, no drugs: no ESKAPE! An update from the infectious diseases society of America. Clin Infect Dis 48: 1–12.

21. Knaus WA, Draper EA, Wagner DP, Zimmerman JE (1985) APACHE II: a severity of disease classification system. Crit Care Med 13: 818–829.

22. Nygård ST, Langeland N, Flaatten HK, Fanebust R, Haugen O, et al. (2014) Aetiology, antimicrobial therapy and outcome of patients with community acquired severe sepsis: a prospective study in a Norwegian university hospital. BMC Infect Dis 14: 121.

23. Marra AR, Cal RG, Silva GV, Caserta RA, Paes AT, et al. (2009) Successful prevention of ventilator-associated pneumonia in an intensive care setting. Am J Infect Control 37: 619–625.

24. Marra AR, Cal RG, Durlo MS, Gorra l, Guastelli LR, et al. (2010) Impact of a program to prevent central line-associated bloodstream infection in the zero tolerance era. Am J Infect Control 38: 434–439.

25. Durao MS, Marra AR, Moura DF, Almeida SM, Fernandes CJ, et al. (2010) Tight glucose control versus intermediate glucose control: a quasi-experimental study. Anaesth Intensive Care 38: 1–7.

26. Finfer S, Chinotck DR, Su SY, Blair D, Foster D, et al. (2009) Intensive versus conventional glucose control in critically ill patients. N Engl J Med; 360: 1283–1297.